Document Detail


Study of the efficacy of fluoxetine and clomipramine in the treatment of premature ejaculation after opioid detoxification.
MedLine Citation:
PMID:  16449099     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Premature ejaculation is a common symptom that can provoke relapse in formerly opioid-dependent men after detoxification. The purpose of this study was to compare the efficacy of clomipramine and fluoxetine for the treatment of premature ejaculation in formerly opioid-dependent men after detoxification. Sixty opium-detoxified men with A & B DSM-IV diagnostic criteria for premature ejaculation participated in a prospective two-week descriptive inferential clinical trial after a two-week washout period. The subjects did not consume any other medications but naltrexone for maintenance of an opium-free state. The subjects were randomly divided into two groups of thirty subjects, one group received fluoxetine (10 mg/d for the first and 20 mg/d for the second week), and the other received clomipramine (25 mg/d for the first and 50 mg/d for the second week). Twenty five subjects did not continue the treatment and were lost to follow-up. The severity of the premature ejaculation was graded regarding the subjects' report in weeks 0, 1, and 2. Mann Whitney-U and Wilcoxon non-parametric tests were used for statistical analysis. Fluoxetine (10 mg/d then 20 mg/d) and clomipramine (25 mg/d then 50 mg/d) were both effective in the treatment of premature ejaculation and did not show any difference in efficacy. The severity of premature ejaculation did not show any relation to the subjects' age, education level, opioid type, or route of abuse. Fluoxetine and clomipramine both can be equally used in the treatment of premature ejaculation following opioid detoxification, depending on their side effects and other symptoms in the subjects.
Authors:
Ebrahim Abdollahian; Arash Javanbakht; Kamran Javidi; Ali Akbar Samari; Mansur Shakiba; Mohammad Reza Sargolzaee
Related Documents :
6375709 - Objective evaluation of dextromethorphan and glaucine as antitussive agents.
7884019 - The effect of amitriptyline, doxepin, fluvoxamine, and paroxetine treatment on heart ra...
8562299 - Pharmacokinetic interaction studies between felbamate and vigabatrin.
11110009 - The efficacy of sertraline in panic disorder: combined results from two fixed-dose stud...
24084519 - Patient entrance surface dose measurements using xr-qa2 gafchromic films during mictura...
6130379 - Long-term efficacy of fenfluramine in treatment of obesity.
3836859 - Evaluation of a new pharmaceutical form of nimesulide for the treatment of influenza.
6259 - Effect of ergoline derivative vufb-6638 on the adenohypophysial prolactin concentration...
22816369 - Increased absorption of mangiferin in the gastrointestinal tract and its mechanism of a...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions     Volume:  15     ISSN:  1055-0496     ISO Abbreviation:  Am J Addict     Publication Date:    2006 Jan-Feb
Date Detail:
Created Date:  2006-02-01     Completed Date:  2006-06-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9208821     Medline TA:  Am J Addict     Country:  United States    
Other Details:
Languages:  eng     Pagination:  100-4     Citation Subset:  IM    
Affiliation:
Ibn E Sina Hospital of Psychiatry, Mashhad University of Medical Sciences, Mashhad, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antidepressive Agents / therapeutic use*
Clomipramine / therapeutic use*
Dose-Response Relationship, Drug
Ejaculation / drug effects*
Fluoxetine / therapeutic use*
Follow-Up Studies
Heroin / adverse effects
Heroin Dependence / rehabilitation
Humans
Male
Opioid-Related Disorders / rehabilitation*
Opium / adverse effects
Prospective Studies
Serotonin Uptake Inhibitors / therapeutic use*
Sexual Dysfunction, Physiological / chemically induced,  drug therapy*
Substance Abuse Treatment Centers
Substance Withdrawal Syndrome / drug therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antidepressive Agents; 0/Serotonin Uptake Inhibitors; 303-49-1/Clomipramine; 54910-89-3/Fluoxetine; 561-27-3/Heroin; 8008-60-4/Opium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Club drug use among youths in treatment for substance abuse.
Next Document:  Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals.